Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)

Franz Zehentmayr, Petra Feurstein,Elvis Ruznic, Brigitte Langer,Brane Grambozov, Marisa Klebermass, Herbert Hüpfel, Johann Feichtinger,Danijela Minasch,Martin Heilmann, Barbara Breitfelder, Claudia Steffal, Gisela Gastinger-Grass, Karoline Kirchhammer, Margit Kazil, Heidi Stranzl,Karin Dieckmann

Radiotherapy and Oncology(2024)

引用 0|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要